Aligos Therapeutics, Inc. Beat Consensus Estimates
Tuesday, May 6, 2025 at 8:00 AM ET
Aligos Therapeutics, Inc. (ALGS) reported a loss of $2.11 per share on revenue of $0.31 million for the first quarter ended March 2025. The consensus estimate was a loss of $2.80 per share on revenue of $1.00 million. The company beat consensus estimates by 24.64% while revenue fell 68.46% compared to the same quarter a year ago.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-2.11
Earnings Whisper®
-
Consensus Estimate
$-2.80
Earnings Surprise
Earnings Growth
Reported Revenue
$311.00 Thou
Revenue Estimate
$1.00 Mil
Revenue Surprise
Revenue Growth